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Circulating tumor DNA (ctDNA) sequencing studies could provide novel insights into the molecular pathology of cancer in sub-
Saharan Africa. In 15 patient plasma samples collected at the time of diagnosis as part of the Ghana Breast Health Study and
unselected for tumor grade and subtype, ctDNA was detected in a majority of patients based on whole- genome sequencing at
high (30×) and low (0.1×) depths. Breast cancer driver copy number alterations were observed in the majority of patients.
npj Precision Oncology            (2021) 5:83 ; https://doi.org/10.1038/s41698-021-00219-7
INTRODUCTION
There is a need to increase diversity in genomic research,
particularly in African populations, where more aggressive early-
onset breast cancers are diagnosed, and non-invasive methods
could provide novel insights for cancer prevention and treat-
ment1. This would have both regional and global impacts. Breast
cancer incidence is rising in Africa and fast becoming the most
common cancer on the continent with a high mortality rate2.
Technological advances in genomic and bioinformatic analysis of
blood-based biomarkers3,4 offer opportunities for translational
molecular oncology studies in Africa that could inform clinical-
decision-making, including precision medicine treatments and
new paradigms for prevention, surveillance, diagnosis, and clinical
management of cancer.
Much of the literature has focused on ctDNA as an early
detection/diagnosis and prognostic tool in high-income countries
where it is not yet known whether ctDNA is a more sensitive
marker than mammography for early-stage cancer detection5. It is
also not known whether it can reduce mortality from breast
cancer in populations with mammography screening programs.
So far, the use of ctDNA as a means for discovery of cancer driver
genes has been limited to advanced metastatic tumors where
there is also access to solid biopsies and the concentration of
ctDNA is above the limit of detection of current sequencing
technologies3.
We were keen to test if cell-free DNA (cfDNA) sequencing
technology could be used to investigate the molecular pathology
of cancer in understudied populations such as in Ghana. While it is
well established that there is international variation in incidence
and mortality rates of breast cancer, the distribution of molecular
genetic markers has been challenging to capture due to biases in
the collection and processing of tumor tissues6. Understanding
the distribution of molecular subtypes of breast cancer can inform
primary and secondary prevention efforts given that different risk
factor associations can help to clarify the natural history of cancer
in understudied populations. Here, we wanted to determine if we
could capture the molecular genetic landscape of tumors through
blood collection, given that public health, primary, and secondary
prevention programs are shaped by differences in tumor biology
and that cancer etiology is poorly understood in Africa and other
low and middle income countries (LMIC).
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In addition to understanding molecular pathology, ctDNA could
also be a means to improve earlier diagnosis. Analysis of survival
across five sub-Saharan countries support that reducing delays to
diagnosis and increasing access to available treatments could
significantly improve survival outcomes7. We recognize that
delays to diagnosis is a multifaceted challenge that requires
improved education and outreach programs, access to preventive
services, and treatment for cancer. We reason that improved
points of care for molecular diagnostics such as cfDNA/ctDNA
studies might all assist in diagnosing patients quicker and
providing them with the appropriate treatments that may be
more effective to improve survival.
Whole-genome sequencing of cell-free DNA (WGS-cfDNA) can
be used to identify mutations from tumor cells that have shed
their DNA into the bloodstream in the form of ctDNA4,8,9.
Mutations in ctDNA have been studied mostly in populations of
European ancestry to investigate utility for diagnosis, screening,
early detection, tumor classification, and monitoring responsive-
ness to treatments3,4. With increased investments in emerging
technologies and bioinformatics, similar molecular oncology and
precision medicine studies might also be possible in Africa10–12.
To establish a proof-of-concept, we used samples from Ghana,
where organized mammography screening programs are lacking
and late presentation is common, with the majority (62%) of
breast cancer patients are diagnosed with tumors >5 cm in size13.
We have previously shown that ~64% of incident breast cancers
in Ghana were below age 55 years and triple negative breast
cancers (TNBCs) were more frequent than in predominantly
European populations1, where data show mammography screen-
ing is less effective14.
Knowledge about the genomic landscape of tumors among
women in Africa is limited; therefore, we tested whether ctDNA is
readily detectable in Ghanaian breast cancer patients. We
hypothesized that WGS-cfDNA in African women with breast
cancer could reveal somatic alterations15 of potential clinical
relevance and provide new genomic insights.
RESULTS
Circulating tumor DNA fractions of Ghanaian women at the
time of breast cancer diagnosis
The 30× WGS-cfDNA analysis indicated that all 15 breast cancer
patients had at least 1% of ctDNA fraction out of total cfDNA
(median [IQR] 3.96% [2.22–8.13%]). A comparison of the estimated
ctDNA fraction from the 30× cfDNA-WGS with the 0.1× WGS-
cfDNA showed high concordance between estimated ctDNA
fractions (Pearson r= 0.99, p= 5.4e−09; Supplementary Fig. 1).
Using 0.1× WGS-cfDNA, a minimum of 1% ctDNA fraction was
detected in 12 (80%) (95% CI 52%–96%, Fig. 1). Comparisons
between ctDNA fractions and clinico-pathological characteristics
were made (Supplemental Fig. 2). Due to the small sample size, we
were limited in power to detect statistically significant differences.
Interestingly, TNBC patients had higher levels of ctDNA compared
to non-TNBC patients (p= 0.04; two-sided Wilcoxon rank sum
test). The four patients with the highest ctDNA fraction were TNBC
patients (out of total 5) which is consistent with other popula-
tions16. Other studies have reported that TNBCs show more
30x WGS
0.1x WGS
Fig. 1 Co-mutation plot showing association between clinical information and genomic characteristics. Patients are represented by the
columns ordered by decreasing ctDNA fraction. The top two rows show bar plots of tumor fractions estimated with ichorCNA from cfDNA
sequenced with 30× WGS-cfDNA (gold bars) and 0.1× WGS-cfDNA (blue bars) (n= 15 patients). The horizontal line across the bar plot shows
the limit of detection of ichorCNA for 0.1× (ctDNA fraction= 3%) and a threshold for 30x (ctDNA fraction= 1%) for the detection of ctDNA.
Immunohistochemical stains for ER, PR and HER2+, age, and tumor size classification are presented. Copy number gain and loss of selected
driver genes in breast cancers are shown in the bottom panel.
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aggressive features17 including being diagnosed at earlier ages,
higher grade, stage, and larger tumor size compared to luminal
types18. However, we observed that the stage of the non-TNBC
patients was similar to that of TNBC patients, and the patient with
the highest ctDNA fraction was a stage 2B TNBC patient.
Copy number profiles of Ghanaian women at the time of
breast cancer diagnosis
Copy number profiling showed extensive amplification and
deletion of multiple chromosomal regions (Fig. 2 and Supple-
mentary Fig. 3) including those containing oncogenes and tumor
suppressor genes associated with breast cancer (Fig. 1)19. We
observed a high frequency (>50%) of copy number gain at three
well-known breast cancer loci that contain potential oncogenes
(chr8p11.23 [ZNF703] n= 8, 53.3%; chr8q24.2 [MYC] n= 9, 60%;
chr19q12 [CCNE1] n= 9, 60%). In The Cancer Genome Atlas
(TCGA), chr8p11.23 was amplified in 12.7% of breast tumors from
patients of African Ancestry (AA) compared to 11.2% of
European Ancestry19. We observed high-level amplification
(more than four copies) of chr8p11.23 in four (27%, 95% CI
8%–55%) Ghanaian samples.
Focal amplification of chr8p11.23 has been associated with
luminal B tumors20,21 and late recurrence22 in women of European
ancestry. The amplification was associated with worse outcomes
for patients compared with those who had no change in copy
number even after adjustment of stage, grade, and cancer
subtype23. In our study, the tumors of patients with high
amplification of chr8p11.23 regions were observed across the
different IHC-defined molecular subtypes of breast cancer. Our
data support ZNF703 as a possible driver gene, which has been
suggested to be relevant in the etiology of breast cancer through
regulation of both mammary basal and luminal progenitors21.
Furthermore, ZNF703 amplification leads to increase in ZNF703
expression levels, which has been associated with decrease in
overall survival for ER positive and luminal B patients24. The
amplification of another potential driver in chr8p11.23 includes
FGFR1, which has been associated with worse outcomes in luminal
A breast cancers20 as well as resistance to endocrine therapy25. A
recent publication suggests that histone H3 lysine 36 (H3K36)
methyltransferase NSD3, may be the target of chr8p11.23
amplification and may suggest potential new therapies26.
Another recurrent high-level amplification event in our Ghana
patient samples was at chr8q24, a region that contains MYC. Nine
patients (60%) had at least a copy gain (CN ≥ 3) of the
chromosomal locus chr8q24. Chr8q24 amplification has been
linked to poor prognosis27. An increase in copy number was
reported in 70–80% of TNBC patients28, which was consistent with
our data where we observed three (60%) of five TNBC patients
harboring high-level amplification of this region. Interestingly,
TNBC patients in our sample showed similar genome-wide copy
number patterns compared to TNBC patients of European
ancestry29. These included loci harboring the two telomerase
genes TERC and TERT, implicating upregulation of telomerase
activity in breast oncogenesis30.
Furthermore, of the two patients classified as HER2+ based on
IHC, only one had increased copy number of the region that
included ERBB2 (50 and 2 copies for patients P08 and P13
respectively), consistent with data showing that classification of
HER2 status was variable for different quantitative assays31.
We compared the ability to predict copy number status for
15 selected breast cancer genes of interest from 0.1× and 30×
WGS data (Supplementary Fig. 4). When we applied a cut-off of 3%
ctDNA fraction (previously described as the limit of detection for
0.1× WGS of metastatic breast3), we observed >46.7% concor-
dance between gene copies from 0.1× WGS and 30× WGS
(Supplementary Fig. 4A). Interestingly, patients with >4% ctDNA
fraction, with the exception of patient P09, had at least 80%
concordance (Supplementary Fig. 4B) between 0.1× WGS and 30×
Fig. 2 Genome-wide copy number profiles of 4 patients from cfDNA sequenced at 30× WGS. The x-axis represents chromosomes (chr1-22:
X) and y-axis shows log2 copy number. Blue represents copy neutral, i.e., chromosomal loci with standard 2 copies (such as chr3, chr4, and
chr5 in P07). Deletions of genomic loci (i.e., chr4p in P01 and P08) are shown in green. Gains (3–4 copies) and amplifications (>4 copies) of
chromosomal loci (such as chr8p12 containing ZNF703 genes in P01, P07, P08, and P15) are shown in brown and red colors, respectively. P08
has amplification of the chr17 locus containing ERBB2. Arrows indicate the gene and estimated copy number (CN) of the predicted segment
by ichorCNA. GU Grade Unknown, G2 moderately differentiated, G3 poorly differentiated, WGS whole-genome sequencing, CN copy number,
ER estrogen receptor, PR progesterone receptor, HER2 human epidermal growth factor receptor 2, ctDNA circulating-tumor DNA.
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WGS copy number profile for these selected breast cancer genes.
Copy number concordance for each gene per patient pair (0.1×
and 30× cfDNA-WGS) with >3% ctDNA was at least 70%
(Supplementary Fig. 4C). These results suggest that prediction of
copy number status for many selected breast cancer genes is
potentially feasible from 0.1× WGS of cfDNA in Ghanaian clinics.
Furthermore, these results reiterate the current limitations of
ctDNA detection in samples with lower tumor fractions3.
DISCUSSION
Our study shows the depth of genomic information that can be
obtained by interrogating WGS-cfDNA from plasma samples of
breast cancer patients in Ghana. This can reveal copy number
alterations and provide more detailed genomic insights into
breast cancer in this and other populations with limited
resources. Our observation of key alterations having similar
frequencies in Ghanaian and AA breast cancer patients suggests
that ctDNA may be a useful method for comparative genomic
studies of breast cancer as well as for other cancers. In particular,
targeted assays for the detection of high copy numbers of
ZNF703/FGFR1/NSD3 and MYC would increase the sensitivity of
their detection in the low fractions of ctDNA circulating in the
blood. As this amplification is established to be associated with
late-stage tumors23, further research is needed to determine
factors associated with its higher frequency, and in particular,
whether it is due to presentation at a late cancer stage or due to
other genetic, environmental or lifestyle associated factors.
This study has some limitations. The unavailability of outcomes
data did not allow us to compare ctDNA fractions across different
outcomes of breast cancer; therefore, further studies are required
to explore the clinical utility of ctDNA in Ghanaian populations.
Our study could have benefited from somatic variant detection
such as insertions (indels) and single nucleotide variants (SNVs).
However, from our previous study, we noted that for sufficient
statistical power, more than 150x target sequencing coverage is
needed to discover these somatic mutations at ctDNA fractions
higher than 10%, and higher coverage is needed in samples with
lower ctDNA3. Therefore, the current depths of sequencing (30×
and 0.1× WGS) is insufficient to reliably identify such somatic
variants. Hence, future studies could incorporate whole exome
sequencing (WES) or high-coverage gene panel sequencing to
determine such somatic mutations of clinical relevance. The lack
of controls and small sample size did not allow us to determine
the specificity and sensitivity of cfDNA-WGS in detecting cancer.
Larger datasets and sequencing results from other populations
with outcome data will enable determination of whether
chromosomal amplifications are enriched in West-African ancestry
or a manifestation of adverse effect of cancer, which would be a
key question to address in promoting precision medicine in
different populations. Future studies to include cancer-free
controls will enable us to evaluate the specificity of cfDNA to
detect cancer in African-clinical settings.
On the African continent, cancer incidence is rising, mortality
rates are high and access to molecular pathology is limited. Non-
invasive methods for molecular tumor subtyping could be
transformative. The rapid advancement of sequencing technolo-
gies and the estimated ctDNA fraction levels (>1%) in this sample
of Ghanaian patients in this study indicate that the exploration of
alternative methods such as methylation-based cfMedip-seq and
panel testing via cfDNA are warranted. These could have high
sensitivity (for at least 0.1% ctDNA fraction) and be suitable for
patients at the time of diagnosis3,4,8. Moreover, the ability to
detect tumors with WGS-cfDNA may open up opportunities to test
additional advances for sample collection methods (such as a
finger-prick blood test32). Since all patients had ctDNA fractions
higher than 1%, targeted gene panels of high depth (>1000×) will
be able to detect nearly all clonal somatic short insertion deletions
mutations in the Ghanaian samples3. For discovery of new driver
genes or mutational signatures detection, 150× WES can be used
in cfDNA samples with more than 8% ctDNA fraction. Also,
including outcome data will enable the study of cfDNA fraction
and copy number as predictive and prognostic biomarker of
breast cancer and response to current therapies in Ghana. New
and affordable sequencing technologies would allow more facile
translation of cancer genomic data to be used at the point of care.
Hence, our study shows that an analysis of ctDNA could be a tool
for future molecular oncology studies in Africa that merits further
investment for cancer etiology, surveillance, molecular oncology
and clinical trial studies that are urgently needed to improve
cancer survival in Africa.
METHODS
Patient selection
This project is based on a case-control study of breast cancer conducted in
collaboration with three hospitals in Ghana responsible for treating most
breast cancers in the country which has been previously described1,13;
Korle Bu Teaching Hospital (KBTH) in Accra and Komfo Anokye Teaching
Hospital (KATH) and Peace and Love Hospital (PLH) in Kumasi. Eligible
cases in this study were women 18–74 years of age who were residents of
defined catchment areas surrounding Kumasi and Accra for at least one
year and who in the preceding year had a lump suspected to be cancer
that resulted in either referral for a biopsy at the study hospitals (KBTH,
KATH, and PLH) or for clinical care. Within the GBHS study we had
identified 15 patients that had duplicate samples which were identified
through quality control analysis to identify genetic duplicates for ongoing
efforts to identify genetic susceptibility variants. As these patients had
multiple plasma samples, and we were not sure if we would be able to
detect cfDNA, these samples represented an excellent opportunity to test
cfDNA and ctDNA protocols that if successful could be used in the wider
collection of over 4000 subjects. These subjects were not selected for any
other characteristics and are a random selected set that shows similar
demographics and tumor characteristics to the rest of the invasive cases in
the study. Demographics and tumor characteristics of the 15 participants
selected for the cfDNA study were similar to the overall patient population,
with a median age at diagnosis of 49.5 (IQR 44.3–57.8) years.
The study was approved by the Special Studies Institutional Review
Board of the National Cancer Institute (Rockville, MD), the Ghana Health
Service Ethical Review Committee and institutional review boards at the
Noguchi Memorial Institute for Medical Research (Accra, Ghana), the
Kwame Nkrumah University of Science and Technology (Kumasi, Ghana),
the School of Medical Sciences at Komfo Anokye Teaching Hospital
(Kumasi, Ghana) and Westat (Rockville, MD). All participants provided
written informed consent.
Clinical specimens–tumor biopsy
In addition to extracting information from medical records into
standardized case abstract forms, study pathologists (Dr. Duggan)
performed a centralized histopathology review of H&E sections from
biopsy formalin-fixed paraffin-embedded (FFPE) blocks sent to the US
(~75% of malignant cases).
Clinical specimens–blood samples
Venous blood samples were collected using a 10ml purple top EDTA tube
at the time of recruitment, which was usually the time of suspected breast
cancer. Purple top tubes were centrifuged and processed within two hours
of collection to avoid red blood cell (RBC) contamination of the separated
plasma layer. Each collected purple-top tube was kept at room
temperature (18–25 °C or 64–77 °F) and processed for a minimum of
15min at 1500 × g/relative centrifugal force (RCF). The top plasma layer
was separated from buffy coat, and red blood cells. Three 1.8 ml plasma
aliquots were stored using cryovials. Processed plasma specimens were
stored at −80 °C freezers. cfDNA was extracted from 2 aliquots of 1.8 ml
plasma samples and sequenced at low depth (0.1x ULPS) and at higher
depth (30× WGS).
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Tumor characterization (tumor grade, size, stage, and
immunohistochemistry)
FFPE blocks received from Ghana were re-embedded prior to obtaining
5 µm H&E sections for pathology review by study pathologists using a
standardized form to capture the quality of the specimens and
histopathology diagnosis and grade of tumors (See Appendix A,
Supplementary Material). IHC data were based on assessment in Ghana
as recorded on case abstract forms. A concordance study comparing IHC
staining results by Ghanaian pathologists from diagnostic blocks in Ghana
and by an NCI pathologist using the study blocks at NCI (i.e., different FFPE
blocks from the same patient) showed good agreement for ER (79%
agreement based on 87 cases) and HER2 (78% based on 76 cases);
however, the agreement for PR was lower (65% based on 86 cases) as
previously described1.
Tumor size was based on the clinical assessment as previously
described13. At the time of biopsy, data were recorded by nurses and
physicians on the presenting symptoms, number of lumps/masses present,
and the approximate size of the lumps/masses from which biopsies were
obtained. For the 15 patients included in the cfDNA study, nine patients
(60%) presented with tumors larger than 5 cm, and the remaining
presented with tumors 2–5 cm1. Nine (75%) of 12 patients with pathologic
grade data were poorly differentiated. For three (20%) patients, grade
information was not available.
Tumor subtypes by immunohistochemistry were defined as previously
described1. Immunohistochemical (IHC) staining was available for the
majority of patients selected for the cfDNA study and was used to classify
proxies of molecular subtypes (Fig. 1): Luminal A (ER+ or PR+ and HER2−,
n= 6, 40%), Luminal B (ER+ or PR+ and HER2+, n= 1, 6.7%), HER2-
enriched (ER−, PR− and HER2+, n= 2, 13%) and triple negative breast
cancer (TNBC)/basal (ER−/PR−/HER2−, n= 5, 33.3%)33 and indeterminate
(missing ER, PR, and HER2 IHCs, n= 1, 7%).
Of the 15 participants selected, clinical stage was available for 73.3%
(n= 11) of patients, 13.3% (n= 2) were stage 2B, 60% (n= 9) were stage 3
(of which 44.4% were 3A, 44.4% were 3B and 11.1% was 3C) and 26.7%
(n= 4) had no stage information available.
cfDNA extraction from whole blood
cfDNA extraction, library preparation, and sequencing were conducted at
the Broad Institute’s Genomics Services as fee-for-service according to their
protocols3. Whole blood was collected in EDTA tubes and processed for
plasma fractionation within 3 h of blood draw. Blood tubes were
centrifuged at 1900 × g for 10 min and plasma was transferred to second
tube before further centrifugation at 15,000 × g for 10 min. Supernatant
plasma was stored at −80C until cfDNA extraction. cfDNA was extracted
using the QIAsymphony DSP Circulating DNA Kit according to the
manufacturer’s instructions, with 6.3 mL of plasma as input and with a
60 μL DNA elution (Qiagen, 2017). Whole blood was collected in EDTA
tubes and processed for plasma extraction utilizing two spins. Blood tubes
were centrifuged at 1900 × g for 10 min and plasma was transferred to a
second tube before further centrifugation at 15,000 × g for 10 min.
Supernatant plasma was stored at −80C until cfDNA extraction. The
preferred starting input volume is 6.3 mL plasma, if a sample did not meet
this input phosphate-buffered saline (PBS) was added. cfDNA was
extracted using the QIAsymphony DSP Circulating DNA Kit according to
the manufacturer’s instructions. This was a magnetic-particle technology-
based chemistry used in conjunction with the QIAsymphony SP instrument
manufactured by Qiagen. The cfDNA was bound to magnetic particles. The
particle-bound cfDNA was separated from the solution using a covered
magnetic rod head. Several wash steps followed to eliminate debris and
protein residues from the sample. The machine finished with a 60 μL
cfDNA elution.
Library construction
Initial DNA input was normalized to be within the range of 25–52.5 ng in
50 μL of TE buffer (10mM Tris HCl 1 mM EDTA, pH 8.0) according to
picoGreen quantification. Library preparation was performed using a
commercially available kit provided by KAPA Biosystems (KAPA HyperPrep
Kit with Library Amplification product KK8504) and IDT’s duplex UMI
adapters. Unique 8-base dual index sequences embedded within the p5
and p7 primers (purchased from IDT) were added during PCR. Enzymatic
clean-ups were performed using Beckman Coultier AMPure XP beads with
elution volumes reduced to 30 µL to maximize library concentration.
Post library construction quantification and normalization
Library quantification was performed using the Invitrogen Quant-It broad
range dsDNA quantification assay kit (Thermo Scientific Catalog: Q33130)
with a 1:200 PicoGreen dilution. Following quantification, each library was
normalized to a concentration of 35 ng/µL, using Tris-HCl, 10 mM, pH 8.0.
Library pool creation for ultra-low pass sequencing
In preparation for the sequencing of the ultra-low pass libraries (ULP),
approximately, 4 µL of the normalized library was transferred into a new
receptacle and further normalized to a concentration of 2 ng/µL using Tris-
HCl, 10 mM, pH 8.0. Following normalization, up to 95 ultra-low pass WGS
samples were pooled together using equivolume pooling. The pool was
quantified via qPCR and normalized to the appropriate concentration to
proceed to sequencing.
Cluster amplification and sequencing
Cluster amplification of library pools was performed according to the
manufacturer’s protocol (Illumina) using Exclusion Amplification cluster
chemistry and HiSeq X flowcells. Flowcells were sequenced on v2
Sequencing-by-Synthesis chemistry for HiSeq X flowcells. The flowcells
were then analyzed using RTA v.2.7.3 or later. Each pool of ultra-low pass
whole-genome libraries was run on one lane using paired 151 bp runs. For
30× WGS, the same approach used for ULP Unique Molecular Identifiers
(UMI) were adopted. We added extra lanes of sequencing to the ULP
library to achieve 30x.
Next-generation sequencing (NGS) data preprocessing
Raw reads in the form of.fastq files were preprocessed using the GATK best
practices for NGS data (Fig. 1). This involves mapping of raw reads to
human reference genome (Hg19/GRCh37) using Burrows-Wheeler Aligner
(BWA-MEM) algorithms34 to generate a Sequence Alignment/Map (SAM)
file of mapped reads. Sam files were converted to a binary alignment
format (BAM) file of aligned reads35.
Duplicate reads from polymerase chain reaction (PCR) during the library
preparation step of sequencing were removed with “gatk markduplicates”
software to allow us to confidently detect which DNA segments are
amplified or delete due to carcinogenesis36. The base quality score
recalibration (BQSR) step which employs machine learning algorithms
(GATK BaseRecalibrator tool) to model the systematic errors from the
sequencing machine and subsequent correction with gatk ApplyBQSR tool
were done to produce an analysis-ready-bam file for tumor fraction
estimation, ploidy, and copy number aberrations using ichorCNA software.
Quality control (QC) including fragment size distribution was evaluated
(Supplementary Fig. 5).
All the data preprocessing steps were carried out in Terra (https://app.
terra.bio/), a cloud-based analysis platform with publicly available NGS
workflows developed by the Broad Institute in collaboration with
Google Cloud.
Tumor fraction detection and copy number profiles prediction
To estimate the tumor fraction (cell-free DNA originating from neoplastic
cells) and copy number alterations, the ichorCNA software was used3. The
software accepts an analysis-ready-bam file as input and simultaneously
estimates tumor fractions and copy number profiles through a three-step
process (1) dividing the genome into non-overlapping windows of specific
length and computing read coverage within each bin, (2) read normal-
ization; correcting for Guanine-Cytosine content, replication timing,
mappability of reads, (3) tumor fraction estimation and CNA prediction;
implemented using Hidden Markov Models (HMM) segmentation algo-
rithm to find neighboring bins as genomic regions that are amplified or
deleted together and the expectation-maximization algorithms to estimate
the parameters of the model.
For 0.1x ULPS analysis, ichorCNA (v0.2.0) release version (https://github.
com/broadinstitute/ichorCNA) was used with default settings (https://github.
com/broadinstitute/ichorCNA/blob/master/scripts/snakemake/config/config.
yaml).
Briefly, the configuration settings are the following:
A 1MB bin size was used to compute coverage. The following resources,
Guanine+ Cytosine (GC) score, and mappability all in 1MB.wig file format
for hg19 were used to normalize reads when running ichorCNA.
Centromere resource files based on UCSC (GRCh37.p13) were downloaded
from UCSC and used to mask repetitive sequences in the human genome
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that the aligner may have erroneously mapped to. A panel of normals
(PoN) from 27 healthy donors provided in the ichorCNA package as a
resource was used. The threshold applied for the minimum mapping score
was 0.75. To control segmentation, which will ultimately affect sensitivity,
the transition probabilities were set as ichorCNA_txnE= 0.99 and
ichorCNA_txnStrength=100. The non-tumor fraction parameter restart
values of 0.5, 0.6, 0.7, 0.8, 0.9, 0.95 were used. Tumor ploidy restart values
of 2 and 3 were set as parameters. Subclonal copy number (1,3) was set as
part of the parameters. The maximum copy number value of 5 and
Student’s-t likelihood model were set as parameters. Solutions for each
parameter restart were ranked by the log-likelihood value, and only
solutions were included if the following criteria were met: Maximum
fraction of genome accounted as subclonal was <0.5, the maximum
fraction of genome in subclone was <0.7. Optimal solutions were selected
based on the log-likelihoods. Manual inspection of these solutions were
performed to confirm the results.
In the 30× WGS analysis, an updated version of ichorCNA (https://github.
com/GavinHaLab/ichorCNA) was used with custom configurations to
analyze deeper WGS data and to increase the sensitivity needed to be
able to detect low tumor fractions. Parameters used for analysis are stored
as config files and are publicly available on GitHub (https://github.com/
sahuno/cfDNA_Ghana_pilot_GBHS/tree/master/scripts/ichorCNA_configs/
WGS_30x_GBHS_ichorCNA_config).
The key distinguishing steps here are that;
(1) mappability was accounted for
(2) ichorCNA_txnStrength was decreased from default value of 10,000
to 100 to employ more segments leading to higher sensitivity.
(3) The ichorCNA_txnE used was 0.99 to increase sensitivity.
(4) The –minSegmentBins was reduced from 50 to 20
(5) The –altFracThreshold was reduced 0.05 to 0.01
Annotation of somatic copy number variants
To annotate copy number alterations, Ensembl genes37 (human reference
genome GRCh37.p13) with coordinates (Chromosomes 1:22, X, Y, without
patches) were retrieved from Ensembl legacy website http://grch37.ensembl.
org/biomart/martview/2c80f6edb70f976fa9dbcdc5127d8cf0 (accessed date;
Friday, February 14, 2020) programmatically with R package Biomart37.
The following attributes were used to query reference genes from
Ensembl, Gene stable ID, Chromosome/scaffold name, Gene start (bp),
Strand (+/−), Gene end (bp), Gene name, Human Genome Organization
(HUGO) Gene Nomenclature Committee (HGNC) symbol, Gene type. The
queried Ensembl gene list with coordinates and metadata and copy
number segments were converted to Genomic ranges object using the
‘GenomicFeatures‘ package to allow complete overlap between unique
genes and copy number segments. The Genomic ranges object is a type of
object in R used to conveniently store gene information (chromosome,
start position, end position, strand) and other metadata of the gene (gene
name, gene ID, HGNC symbol, etc.). For simplicity, the HGNC symbols
(unique and meaningful naming schemes for known human genes) of
annotated genes were used throughout the analysis38.
The frequency of copy number changes was calculated for a subset of
genes known to be recurrently altered in chromosomal segments
extracted from TCGA (cbioportal, pan cancer breast study) sorted
according to GISTIC scores/q-value. GISTIC (Genomic Identification of
Significant Targets in Cancer) is an algorithm for detecting possible cancer
driver genes in copy number profiles by evaluating the frequency and
amplitude of the events (loss and/or gain of genomic regions)39. Hence the
associated GISTIC q-value and score was the metric used for accepting
possible drivers39.
To determine the frequency of amplification of known breast cancer
genes between African and European ancestry, the TCGA breast cancer
(pan-cancer) via cbioportal (https://www.cbioportal.org/) was used.
Metrics for determining concordance between 0.1× WGS and
30× WGS for copy number detection
To determine whether similar copy number alterations could be detected by
sequencing cfDNA at 0.1× WGS and 30× WGS, we developed two metrics to
quantitatively test this out. Using a list of 15 known cancer genes (as shown
in CoMut plot) we calculated (1) copy number concordance per gene level
(Eq. 1) (2) copy number concordance at the cohort level (Eq. 2).
In generating copy number concordance per gene level, for each
patient, we assigned the value ‘1‘ for a gene copy number match between
0.1× and its 30× WGS. A mismatch was assigned a “0”. For simplicity,
amplifications and high amplifications were recategorized as copy gain
and only gain, loss, neutral were used for this exercise. We then calculated
the sum of matches and mismatches for each gene across our samples
with at least 3% ctDNA fraction and divided by the total number of
samples with ≥3% ctDNA fraction and expressed as a percentage. The 3%
ctDNA fraction cut-off was used following the observation that copy
number events were more similar as ctDNA fraction increased. Similar
observations were found in benchmark exercises using ichorCNA among
metastatic breast and prostate cancer3.
GeneX ¼
1ðpatient 1 GeneX 01xULPS ¼¼ patient 1 GeneX 30xWGSÞþ
0ðpatient 2 GeneX 01xULPS≠patient 2 GeneX 30xWGSÞ þ :¼
1ðpatient n GeneX 01xULPS ¼¼ patient n GeneX 30xWGSÞþ
0ðpatient n GeneX 01xULPS≠patient n GeneX 30xWGSÞ
total number of patients ðcfDNA fraction  3%Þin cohort  100%
(1)
To determine concordance at the cohort level, copy number match of
each gene from sample sequenced at 0.1× and its pair sequenced at 30×
WGS was assigned a ‘1‘ whereas for a mismatch, a value of ‘0‘ was assigned
(Eq. 2). Amplifications and high amplifications were recategorized as copy
gain, for simplicity, therefore only copy gain, loss, and neutral were used.
For each patient we summed up the number matches and mismatches for
all genes, divided by the total number of genes (in the CoMut plot) and
expressed as percentage. We showed that patients with higher ctDNA
fractions had higher percentage of concordance for copy number
detection between 0.1× and 30× WGS.
patient 1 01xULPS&30xWGS ¼
1ðpatient 1 GeneA 01xULPS ¼¼ patient 1 GeneA 30xWGSÞþ
0ðpatient 1 GeneB 01xULPS≠patient 1 GeneB 30xWGSÞ þ ¼ :
1ðpatient 1 GeneX 01xULPS ¼¼ patient 1 GeneX 30xWGSÞÞ
total number of genes of interest
 100%
(2)
patient n 01xULPS&30xWGS ¼
1ðpatient n GeneA 01xULPS ¼¼ patient n GeneA 30xWGSÞþ
0ðpatient n GeneB 01xULPS≠patient n GeneB 30xWGSÞ þ ¼ :
1ðpatient n GeneX 01xULPS ¼¼ patient n GeneX 30xWGSÞÞ
total number of genes of interest
 100%
Statistical analysis
Median and interquartile (IQR) of ctDNA fractions were calculated and
compared with clinico-pathological variables (age, grade, stage, and
subtypes. Pearson correlation analysis was used to calculate the Pearson
correlation coefficient between ctDNA fractions from cfDNA sequenced at
30× WGS and 0.1× WGS. A two-tailed Mann–Whitney U Test was used to
calculate the difference in ctDNA fractions for ER+ vs ER−, <50 years vs 50
years and above, grade 2 vs grade 3 tumors and medium vs large-sized
tumors. The two-sided Wilcoxon signed-rank test was used to calculate
significant differences between ctDNA fractions between TNBCs and Non-
TNBC breast cancers. P values <0.05 were considered significant.
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